Sunday, November 8, 2026

GBP/EUR Bearish Momentum: 0.82% Down In The Last 5 Sessions

ViaNews Editorial Team

August 28, 2023

GBP/EUR Bearish Momentum: 0.82% Down In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.82% for the last 5 sessions. At 17:06 EST on Monday, 28 August, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 7.657% up from its 52-week low and 1.104% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.11%, a positive 0.01%, and a positive 0.26%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.21% (last week), 0.24% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy stabilizes above 146.00 as yields, US dollar retreat, clues about fed–boj divergence eyed. According to FXStreet on Monday, 28 August, "It should be noted that the recently mixed details of Japan's Coincident Index for June and the Leading Economic Index for the said month also prod the USD/JPY pair traders.", "Looking ahead, USD/JPY pair traders should seek clues to justify the monetary policy divergence between the BoJ and the Fed for clear directions. "
  • Usd/jpy consolidates its gains around 146.50 on the fed’s powell hawkish stance. According to FXStreet on Monday, 28 August, " On the US Dollar front, hawkish comments from the central banks' policymakers limit the upside of the Japanese Yen and support the USD/JPY pair. ", "The events will be critical for determining a clear movement for the USD/JPY pair."
  • Usd/jpy technical analysis: upward trend is stronger - 28 August 2023. According to DailyForex on Monday, 28 August, "Accordingly, the dollar pair against the yen USD/JPY jumped towards the resistance level of 146.63 after declining in the middle of the trading of the same week towards the level of 144.53. ", "At the end of last week's trading, the price of the USD/JPY currency pair got a strong positive boost from hints from the officials of the American central bank to continue the pace of raising the American interest rate. "
  • Usd/jpy consolidates around mid-146.00s, bulls have the upper hand near YTD peak. According to FXStreet on Monday, 28 August, "The USD/JPY pair kicks off the new week on a subdued note and oscillates in a narrow trading band around mid-146.00s through the Asian session, just below its highest level since November 2022 touched on Friday.", "This, in turn, might provide some impetus to the USD/JPY pair ahead of this week's important US macro data scheduled at the beginning of a new month, including the closely-watched monthly employment details - popularly known as the NFP report on Friday."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com